Connect with Our Experts
Despite a growing pipeline and global need, Parkinson’s Disease continues to challenge drug developers with complex patient needs and high late-phase failure rates. To increase the odds of success, clinical trial strategies must evolve—prioritizing innovative design, meaningful endpoints, and the patient experience.
Our experts will guide you toward success.
- Design smarter, patient-first studies: Build protocols that accommodate the variability of PD and reflect real-world patient needs.
- Strengthen trial endpoints and symptom measurement: Select appropriate scales and protect data integrity across diverse trial sites.
- Engage advocacy groups for better enrollment: Leverage trusted partners to improve recruitment, education, and retention.
- Implement innovative study designs: Apply adaptive strategies that support efficiency without compromising scientific rigor.
- Navigate regulatory and operational complexity: Get guidance from early-phase planning through global trial execution.
Meet with our experts:
Antonio Hernandez, PsyD – Vice President, Program Strategy, Neuroscience
Melissa Snyder, PhD – Executive Director, Program Strategy, Neuroscience